This study looks at orforglipron, a new medicine, to see if it is safe and helpful for people with Type 2 Diabetes (T2D). People in the study have trouble controlling their blood sugar even though they are taking insulin glargine (a type of insulin), and maybe metformin (a diabetes pill) or SGLT-2 inhibitors (another type of diabetes medicine). The study takes about 46 weeks and might need up to 20 visits to the doctor. People can join if they have T2D, have specific blood sugar levels, and have been on a stable dose of insulin glargine for at least 90 days. They should also have a stable body weight and not start any new intense diets or exercises. Some cannot join if they have serious heart problems, certain liver diseases, or pancreatitis (an inflamed pancreas).

• The study lasts 46 weeks with up to 20 doctor visits.
• Participants must have Type 2 Diabetes and stable insulin glargine use.
• People with serious heart issues or liver disease cannot join.